Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and mk 2461

lapatinib has been researched along with mk 2461 in 2 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(mk 2461)		Trials
(mk 2461)		Recent Studies (post-2010) (mk 2461)
1,9193051,44216014

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)mk 2461 (IC50)
Aurora kinase AHomo sapiens (human)0.29
Tyrosine-protein kinase JAK2Homo sapiens (human)0.23
Tyrosine-protein kinase ABL1Homo sapiens (human)7.8
High affinity nerve growth factor receptorHomo sapiens (human)0.046
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.64
Hepatocyte growth factor receptorHomo sapiens (human)0.184
Cytochrome P450 3A4Homo sapiens (human)7.1
Fibroblast growth factor receptor 1Homo sapiens (human)0.065
Cytochrome P450 2C9 Homo sapiens (human)1.2
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.1
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.01
Fibroblast growth factor receptor 2Homo sapiens (human)0.039
Fibroblast growth factor receptor 3Homo sapiens (human)0.05
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.078
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.044
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.022
Macrophage-stimulating protein receptorHomo sapiens (human)0.007
Tyrosine-protein kinase MerHomo sapiens (human)0.024
BDNF/NT-3 growth factors receptorHomo sapiens (human)0.061

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Russu, WA; Shallal, HM1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

2 other study(ies) available for lapatinib and mk 2461

ArticleYear
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017